tradingkey.logo

Impact Biomedical Inc

IBO
0.511USD
-0.051-9.03%
收盘 12/24, 13:00美东报价延迟15分钟
6.23M总市值
亏损市盈率 TTM

Impact Biomedical Inc

0.511
-0.051-9.03%

关于 Impact Biomedical Inc 公司

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc简介

公司代码IBO
公司名称Impact Biomedical Inc
上市日期Sep 16, 2024
CEOHeuszel (Frank D)
员工数量2
证券类型Ordinary Share
年结日Sep 16
公司地址1400 Broadfield Blvd.
城市HOUSTON
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编77084
电话15852321500
网址https://www.impactbiomedinc.com/
公司代码IBO
上市日期Sep 16, 2024
CEOHeuszel (Frank D)

Impact Biomedical Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Jason Grady
Mr. Jason Grady
Director
Director
182.00
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
--
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Jason Grady
Mr. Jason Grady
Director
Director
182.00
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Chan (Heng Fai Ambrose)
0.34%
BlackRock Institutional Trust Company, N.A.
0.24%
The Vanguard Group, Inc.
0.10%
Heuszel (Frank D.)
0.09%
Two Sigma Investments, LP
0.06%
其他
99.18%
持股股东
持股股东
占比
Chan (Heng Fai Ambrose)
0.34%
BlackRock Institutional Trust Company, N.A.
0.24%
The Vanguard Group, Inc.
0.10%
Heuszel (Frank D.)
0.09%
Two Sigma Investments, LP
0.06%
其他
99.18%
股东类型
持股股东
占比
Individual Investor
0.43%
Investment Advisor
0.40%
Hedge Fund
0.06%
Investment Advisor/Hedge Fund
0.05%
Corporation
0.02%
其他
99.04%

机构持股

更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
25
542.17K
4.45%
+223.27K
2025Q2
27
5.00M
43.10%
+213.82K
2025Q1
27
9.94M
82.23%
+3.86M
2024Q4
21
6.56M
57.06%
+6.27M
2024Q3
14
6.41M
55.73%
+6.41M

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Chan (Heng Fai Ambrose)
351.56K
2.88%
-3.92M
-91.76%
Apr 04, 2025
BlackRock Institutional Trust Company, N.A.
252.73K
2.07%
+222.06K
+723.90%
Jun 30, 2025
The Vanguard Group, Inc.
32.44K
0.27%
-94.01K
-74.35%
Jun 30, 2025
Heuszel (Frank D.)
95.47K
0.78%
--
--
Sep 08, 2025
Two Sigma Investments, LP
22.70K
0.19%
+22.70K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
49.87K
0.41%
+26.67K
+114.95%
Jun 30, 2025
Document Security Systems, Inc.
21.26K
0.17%
-161.00K
-88.33%
May 27, 2025
Susquehanna International Group, LLP
30.82K
0.25%
+30.82K
--
Jun 30, 2025
UBS Financial Services, Inc.
39.73K
0.33%
+23.56K
+145.72%
Jun 30, 2025
State Street Investment Management (US)
11.80K
0.1%
--
--
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Impact Biomedical Inc的前五大股东是谁?

Impact Biomedical Inc 的前五大股东如下:
Chan (Heng Fai Ambrose)持有股份:351.56K,占总股份比例:2.88%。
BlackRock Institutional Trust Company, N.A.持有股份:252.73K,占总股份比例:2.07%。
The Vanguard Group, Inc.持有股份:32.44K,占总股份比例:0.27%。
Heuszel (Frank D.)持有股份:95.47K,占总股份比例:0.78%。
Two Sigma Investments, LP持有股份:22.70K,占总股份比例:0.19%。

Impact Biomedical Inc的前三大股东类型是什么?

Impact Biomedical Inc 的前三大股东类型分别是:
Chan (Heng Fai Ambrose)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.

有多少机构持有Impact Biomedical Inc(IBO)的股份?

截至2025Q3,共有25家机构持有Impact Biomedical Inc的股份,合计持有的股份价值约为542.17K,占公司总股份的4.45%。与2025Q2相比,机构持股有所增加,增幅为-38.65%。

哪个业务部门对Impact Biomedical Inc的收入贡献最大?

在--,--业务部门对Impact Biomedical Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI